Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD74 | P04233 | 1/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.43 |
| ▸ | CBX7 | O95931 | 2/20 | 0.43 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.43 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.43 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058161 | 0.83 | MIF (0.52) | CD74MIFIDO1POLBTNIK | |
| SCHEMBL4413144 | 0.81 | HPGD (0.64) | CD74MIFIDO1POLBTNIK | |
| SCHEMBL8877584 | 0.81 | MET (0.49) | CD74MIFIDO1POLBTNIK | |
| SCHEMBL10987080 | 0.80 | TDP1 (0.55) | IDO1POLBKMT2AALDH1A1ALPG | |
| SCHEMBL2149337 | 0.78 | TNIK (0.49) | CD74MIFIDO1POLBTNIK | |
| SCHEMBL9716002 | 0.77 | MIF (0.44) | CD74MIFIDO1POLBTNIK | |
| SCHEMBL18805699 | 0.76 | MIF (0.73) | CD74MIFIDO1POLBTNIK | |
| SCHEMBL3049673 | 0.75 | MAPK1 (0.72) | MIFIDO1ALDH1A1 | |
| SCHEMBL5539784 | 0.74 | CD74 (0.42) | CD74MIFIDO1POLBTNIK | |
| SCHEMBL5539787 | 0.74 | MEN1 (0.59) | POLBKMT2AMEN1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | claimed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | CD74 4847/4885MIF 4473/4885IDO1 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.